WithdrawnNCT00512616

A Glutamate Transporter GLT1, in the Treatment of Bipolarity

Medication studyAges 18–65United States

The study in practice

Understand this study

This study is for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Study start dateAugust 1, 2007

Recruitment status: Withdrawn
Enrollment listed in the registry: 0
Sponsor: National Institute of Mental Health (NIMH)
Sponsor type: Government agency
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 2
Locations: United States
Age range: From 18 Years to 65 Years
Official registry ID: NCT00512616
Official title: Show the full official title
An Investigation of the Efficacy of the Glutamate Transporter GLT 1 in the Treatment of Bipolar Depression

The HopeStage team will email you.

Withdrawn

Bethesda

A listed location does not confirm current availability.

FAQ

Who is behind this study?

The study sponsor is National Institute of Mental Health (NIMH), a government agency.

Does this study involve medication?

Yes. The study involves medication, including Ceftriaxone.

Who can participate?

This study is for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as withdrawn.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.